Business
HLS Therapeutics Announces High Risk of Atherosclerotic Cardiovascular Events Projected in People with Elevated Triglycerides Without Established Atherosclerotic Cardiovascular Disease
HLS Therapeutics Announces High Risk of Atherosclerotic Cardiovascular Events Projected in...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nHLS Therapeutics Announces High Risk of Atherosclerotic Cardiovascular Events Projected in People with Elevated Triglycerides Without Established Atherosclerotic Cardiovascular Disease\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, March 19, 2019\n\n\n\nTORONTO, March 19, 2019 /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that on March 16, 2019, Amarin Corporation plc (NASDAQ:AMRN), released the presentation of data and analysis which concluded that over nine million atherosclerotic cardiovascular disease (ASCVD) events are projected to occur in the United States within the next ten years in adults aged 40-79 for whom ASCVD is not established. Over three million of these events are projected to occur in persons with elevated triglyceride (TG) levels of ≥150 mg/dL, including approximately one million events in statin users. The research used proportions of risk by TG level and reflected that increased cardiovascular (CV) risk was associated with higher TG levels. This research highlights that millions of CV events will occur in people that haven't had a CV event and supports the need for expanded education about the use of TG levels as an identifier of cardiovascular risk. It also highlights that there is an urgent need to address this immense risk and examine the capacity of lifestyle modification and other therapies to attenuate ASCVD risk beyond cholesterol management in patients with elevated TG levels. \nThese data and analysis were presented in a poster entitled \"Burden of Atherosclerotic Cardiovascular Disease Risk in Persons with Elevated Triglyceride Levels According to Statin Use\" at the American College of Cardiology's (ACC) 68th Annual Scientific Session in New Orleans, LA. The research used the ACC/AHA risk calculator and NHANES data with corresponding projected population sizes to estimate a 10-year risk of cardiovascular death, nonfatal myocardial infarction (MI or heart at...